218results about "Assay labels" patented technology

Provided herein are methods of determining a location or presence of a target analyte in a biological sample by detecting oligonucleotide-conjugated binding agents.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Described herein are methods for screening for a disease state. The method may include obtaining multiple data sets and identifying the disease state based on a combination of the data sets. The data sets may include biomolecule measurements obtained by multiple methods, such as through the use of particles and reference biomolecules.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

A reagent combination, a kit, a detection system and a detection method for detecting a small molecule substance. In the condition that a solution to be tested does not contain or contains a small amount of the small molecule substance, an antibody binds to a substrate protein conjugate to form an immune complex, a stem-loop structure is generated by means of a complementary pairing among a plurality of nucleic acid molecules, a first fluorescent group excites a second fluorescent group to emit a second fluorescence on the basis of fluorescence resonance energy transfer, and the content of the small molecule substance is calculated. In the condition that the solution to be tested contains a large amount of the small molecule substance, the immune complex and the stem-loop structure cannot be formed, and the second fluorescent group cannot emit the second fluorescent.

The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes.

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.

Provided herein are compositions and methods for the identification of an expression profile in a single cell or population of cells. Kits for use with the disclosed methods are also provided, including antibodies, with a unique molecular identifier and antibody identifier, and primers for amplification of the antibody identifier sequence.

The invention relates generally to peptide biomarkers with specific ionization characteristics to directly quantify one or more target HPPD proteins in biological samples, including crop plant samples, by liquid chromatography coupled tandem mass spectrometry multiple reaction monitoring (MRM). The peptide biomarkers in combination with MRM-based methods may be used to quantify a single target protein or multiple target proteins within a crop plant, such as maize, utilizing selected peptide biomarkers either alone or in combination. The present disclosure allows for broad based, reliable quantitation in different biological matrices, including plant matrices. Also provided are different peptide biomarker combinations that can be used to perform the methods of the invention.

A pharmaceutical composition for isotope-selective modulation including at least one isotope selected from the group consisting of 1H, 6Li, 12C, 10B, 14N, 16O, 17O, 24 Mg, 26 Mg, 28Si, 29Si, 32S, 33S, 39K, 35Cl, 40Ca, 42Ca, 43Ca, 50V, 50Cr, 52Cr, 54Fe, 56Fe, 58Ni, 60Ni, 61Ni, 63Cu, 64Zn, 66Zn, 92Mo, 94Mo, 95Mo, 96Mo, 74Se, 76Se, 77Se, 78Se, 70Ge, 72Ge, 73Ge, 79Br, 85Rb, 107 Ag, 130Ba, 132Ba, 134Ba, 135Ba, and 136Ba, wherein said at least one selected isotope is enriched to exceed its relative isotopic ratio found in a naturally occurring sample of the same chemical element. Methods for its use include investigating the isotopic signatures, intervening with isotopic fractionation in mammals.

To provide a composition and method for executing assay measurement.SOLUTION: The present disclosure provides a composition, a reagent, a kit, a system, a system component, and a method for performing assays. More specifically, the present disclosure relates to an assay composition for detecting luminescence, including an alkyldiethanolamine, e.g., N-butyldiethanolamine (BDEA). In some embodiments, the assay composition includes 2-dibutylaminoethanol (BDAE).SELECTED DRAWING: None

This relates to compositions and methods for performing assay measurements. [Solution] This disclosure provides compositions, reagents, kits, systems, system components, and methods for carrying out assays. More specifically, this disclosure relates to assay compositions for detecting luminescence, comprising alkyldiethanolamines, for example, N-butyldiethanolamine (BDEA). In embodiments, the assay composition comprises 2-dibutylaminoethanol (BDAE).

Single-cell multi-omics by co-encapsulating a single cell with two beads, the first an RNA barcoding bead having barcoded mRNA capture primer oligonucleotides attached on the bead surface; and the second a DNA barcoding bead having two types of oligonucleotides releasably attached to the surface: (1) barcoded adapter oligonucleotides that are complementary to oligonucleotides bound to the transposase that are eventually incorporated into gDNA fragments and (2) polyadenylated barcoded oligonucleotides containing the same barcode sequence as the adapters. In addition, integrated analysis of RNA and protein, including intracellular protein, from individual cells using similar co-encapsulation of a single cell, an RNA barcoding bead, and with / without a specific or non-specific protein binding bead in a microwell, to avoid protein fixation by first lysing the cell to liberate intracellular contents, and then capturing protein either on a solid surface or in solution with barcoded affinity reagents.

This specification provides methods, assays, and reagents useful for sequencing proteins. Protein sequencing in a broad sense involves observing valid amino acid identity and order, which is useful for sequencing a single polypeptide molecule or multiple molecules of a single polypeptide. In one embodiment, this method is useful for sequencing multiple polypeptides. The methods and reagents described herein may be useful for high-resolution investigations of the proteome and may enable ultra-sensitive diagnostics, which are important for the early detection of diseases. [Solution] A method for identifying the terminal amino acids of a peptide, (a) A step of contacting the peptide with a ClickP compound, wherein the ClickP compound binds to the terminal amino acids or terminal amino acid derivatives of the peptide to form a ClickP peptide complex, (b) A step of attaching the ClickP peptide complex to a substrate, (c) A step of cleaving the complex from the peptide, thereby providing the ClickP amino acid complex, (d) A method comprising the step of detecting the ClickP amino acid complex.

Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

Systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

Provided herein are methods of characterising a target polypeptide as it moves with respect to a nanopore. Also provided are related kits, systems and apparatuses for carrying out such methods.

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.

The present invention relates to a method for determining the sex of a fetus in an ungulate.

The disclosure relates to methods, compositions, and kits for detecting and analyzing surface marker displaying agents (SMDAs). The disclosure further relates to methods for detecting, diagnosing, monitoring response to treatment or recurrence, or predicting overall survival, progression-free survival or duration of response in a subject suspected of having colorectal cancer (CRC) comprising performing one or more assays on at least one biological sample from the subject to detect one or more specific populations of EVs.

Methods and systems are provided for detecting a binding interaction between a binding reagent and an analyte under equilibrium binding conditions. The binding interaction can be detected by the formation of an interaction identification moiety. The interaction identification moiety can be detected even after the binding reagent dissociates from the analyte.

Systems and methods for multiplex detection through measurement of localized fluorescence ratios are disclosed herein. This can include creating a plurality of capture structures that each include a detection portion that can couple with a target analyte and a stem that can include a capture structure code uniquely identifying a type of the capture structure. The capture structures can be attached to a sample surface and mixed with a sample containing a plurality of target analytes. A location and the capture structure code of each of the capture structures can be determined. A location at which a target analyte is bound to one of the capture structures can be identified, and the target analyte can be determined based on the capture structure code of the capture structure at the location at which the target analyte is bound to one of the capture structures.

Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds and methods of using the compounds.

Disclosed herein are methods for detecting target protein interactions in biological samples, and kits for carrying out the methods.

Methods and compositions for detecting isoaspartate residues in polypeptides using mass spectrometry, and for distinguishing isoaspartate residues from aspartate and / or asparagine residues in a polypeptide using MS analysis. Polypeptides containing one or more isoaspartate residues, or suspected of containing one or more isoaspartate residues, are treated with L-isoaspartyl methyltransferase (PIMT), which is able to selectively modify isoaspartate and impart a mass change to the amino acid residue. The polypeptide is then analysed using mass spectrometry, where a mass change caused by the PIMT reaction is detected and characterized. Preferably, these methods are able to be performed without the use of liquid chromatography or other similar separation techniques prior to mass spectrometry analysis.

The invention relates to methods and kits for assessing brain injury, e.g., traumatic brain injury resulting from blast exposure. The invention provides methods of quantifying the amount of phosphorylated tau or total tau in a biological sample. The invention further provides a method of determining the number of blast exposures experienced by a subject. Also provided herein are kits for detecting phosphorylated tau or total tau in a biological sample.